Free Trial
NASDAQ:ENTA

Enanta Pharmaceuticals Q2 2025 Earnings Report

Enanta Pharmaceuticals logo
$6.99 -0.13 (-1.83%)
Closing price 08/7/2025 04:00 PM Eastern
Extended Trading
$6.85 -0.14 (-2.06%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Enanta Pharmaceuticals EPS Results

Actual EPS
-$1.06
Consensus EPS
-$1.04
Beat/Miss
Missed by -$0.02
One Year Ago EPS
N/A

Enanta Pharmaceuticals Revenue Results

Actual Revenue
$14.93 million
Expected Revenue
$15.96 million
Beat/Miss
Missed by -$1.04 million
YoY Revenue Growth
N/A

Enanta Pharmaceuticals Announcement Details

Quarter
Q2 2025
Time
Before Market Opens
Conference Call Date
Monday, May 12, 2025
Conference Call Time
12:30PM ET

Enanta Pharmaceuticals Earnings Headlines

Q3 Earnings Forecast for ENTA Issued By HC Wainwright
Altucher: Trump’s Great Gain is starting
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.
See More Enanta Pharmaceuticals Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Enanta Pharmaceuticals? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Enanta Pharmaceuticals and other key companies, straight to your email.

About Enanta Pharmaceuticals

Enanta Pharmaceuticals (NASDAQ:ENTA), a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its product pipeline comprises EDP-514, which is in phase 1b clinical development for the treatment of chronic infection with hepatitis B virus or HBV; EDP-938 and EDP-323, which is in phase II clinical development for the treatment of respiratory syncytial virus; EDP-235, which is in phase II clinical development for the treatment of human coronaviruses; and Glecaprevir, which is in the market for the treatment of chronic infection with hepatitis C virus or HCV. The company has a collaborative development and license agreement with Abbott Laboratories to develop, manufacture, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir. Enanta Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in Watertown, Massachusetts.

View Enanta Pharmaceuticals Profile

More Earnings Resources from MarketBeat